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INTRODUCTION
Platelet-rich plasma (PRP) refers to a preparation 
obtained from autologous blood. Inside platelets, there 
are granules filled with growth factors, among the most 
important are platelet-derived growth factor (PDGF), 
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endothelial growth factor (VEGF)(1,2).
Growth factors are polypeptides that are usually 
synthesized by specific tissues and act as local 
regulators of cellular function. These growth factors 
bind to receptors on the target cell membrane, activating 
an intracellular process that produces proteins to be 
used within the cell or exported(3).
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The normal concentration of platelets in peripheral 
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the PRP to be most efficiency, platelet concentration 
$,&9:7*/0* "!&9#7*;>===>===?@:(1,2,4). There are several 
methods for obtaining PRP(5), each with its peculiar 
ability to concentrate the platelets, as well as in the 
release of growth factors by platelets. 
The clinical use of PRP has grown considerably 
and has been applied in various situations: knee 
arthroplasty (TKA), tendon repair, treatment of 
cartilage lesions, and as a bone substitute(6-16). 
PRP has been shown to reduce bleeding, pain, and 
the occurrence of arthrofibrosis when applied in the 
perioperative period in TKA(6,7).
ABSTRACT
Objective: The present study was performed in order to 
evaluate the use of platelet rich plasma associated to bone 
marrow aspirate, substituting autologous iliac bone graft 
in medial opening wedge osteotomy (OWHTO). Methods: 
Twenty-five patients were submitted to tibial opening wed-
ge osteotomy, being divided into two groups. Iliac group: 
14 patients submitted to OWHTO, using autologous iliac 
bone graft to fill the gap. PRP group: 11 patients using 
platelet rich plasma associated to bone marrow aspirate 
to fill the gap. We evaluated bleeding (hemoglobin and 
hematocrit levels) and pain (visual analogic scale-VAS), 
then we compared the groups regarding these variables. 
Results: Differences between the groups were not found 
regarding hemoglobin levels (p=0.820) and hematocrit le-
vels (p=0.323). The groups were not different regarding 
pain measured with VAS (p=0.538). Conclusion: The use 
of platelet rich plasma associated to bone marrow aspirate 
in medial opening wedge osteotomy did not offer advan-
tages over autologous iliac bone graft regarding bleeding 
and pain.
Keywords – Platelet rich plasma; Osteotomy; Tibia; Bone 
substitutes
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The present study aims to evaluate the results with 
regard to pain and bleeding obtained with the application 
of PRP in the proximal tibial osteotomies by addition of 
a medial wedge (TOAMW).
METHODS
This study was approved by the Research Ethics 
Committee of the Universidade de São Paulo. All 
patients signed an informed consent form.
The criteria for inclusion in the study were patients 
with varus knee deformity evaluated using a panoramic 
weight-bearing radiograph of the lower limbs, patients 
between 25 and 60 years of age, absence of systemic 
inflammatory diseases (rheumatoid arthritis, lupus, etc.), 
body mass index (BMI) less than 30kg/m2(17), need for 
correction with the use of wedges between 10 mm and 
15 mm. Diagnosis of unicompartmental osteoarthritis, 
chronic ligament deficiencies, or deformities of the 
lower limbs. The indications for valgus osteotomy 
complied with those recommended in the literature(18-20).
The exclusion criteria were loss to follow-up 
and patient request to be excluded from the study. 
We studied 25 patients randomly divided into two groups 
by drawing lots with replacement performed on the day 
surgery had been scheduled. All surgical procedures in 
this study were performed by the same surgeon.
Patients were separated into two groups. The iliac group 
(IG) was comprised of 14 patients who underwent osteotomy 
with the use of an autologous iliac graft at the osteotomy 
site. The PRP group (PRPG) was comprised of 11 patients 
who underwent osteotomy with the use of a bone substitute 
composed of platelet-rich plasma (PRP) and bone marrow 
aspirate. We called this bone substitute “biological bone graft”.
The most frequent diagnosis in the two groups was chronic 
injury of the anterior cruciate ligament (ACL) (Table 1).
Table 1 – Distribution of patients in the iliac and PRP groups 
according to diagnosis.
Group
TOTAL
Iliac PRP
Diagnosis
p = 0.168
Chronic 
injury of the 
ACL1
6 9 15
42.9% 81.2% 60.0%
Medial OA2
5 1 6
35.7% 9.1% 24.0%
Deformities3
3 1 4
21.4% 9.1% 16.0%
Total
14 11 25
100% 100% 100%
P value regarding the Fisher’s exact test.
1Double varus or triple varus.
2Also includes osteonecrosis.
3Genu varus or fracture sequela.
Table 2 – Distribution of patients in the iliac and PRP groups 
according to size of the wedge used.
Group
TOTAL
Iliac PRP
Wedge size
p = 0.885
10.0 mm
5 3 8
35.7% 27.3% 32.0%
12.5 mm
5 5 10
35.7% 45.5% 40.0%
15.0 mm
4 3 7
28.6% 27.3% 28.0%
TOTAL
14 11 25
100% 100% 100%
P value regarding the Fisher’s exact test.
The groups were homogeneous with regard to 
the size of the wedges used (Table 2).The average 
age of the patients in the iliac and PRP groups was 
45.9 and 37.8 years, respectively (p = 0.014).The 
technique employed to perform the osteotomy was, as 
noted earlier, the addition of a medial wedge, similar 
to the planning and surgical technique described by 
Puddu et al.(19,20).
After osteotomy and plate fixation, the space created 
in the metaphyseal region of the tibia was filled with 
one of the grafts being evaluated (iliac or biological).
To collect the platelets, we used a Haemonetics 
MCS+ 9000 automated cell separator and a 995-E 
plateletpheresis-specific kit (Haemonetics Corp.). In 
this system, the patient’s blood was drained through a 
venipuncture in the antecubital fossa into a separation 
device under continuous centrifugation (Figure 1). 
Figure 1 – Haemonetics MCS+ 9000 automated cell separator. 
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After blood fractionation, a refractive optical analyzer 
singled out the platelet layer and directed its collection 
into a specific disposable bag. The remaining blood was 
completely reinfused into the patient, marking the end 
of a cycle. Sodium citrate was used as an anticoagulant 
in a proportion of one for each 9 ml of processed whole 
blood. Two cycles were usually performed, yielding 
approximately 70 ml of platelet concentrate.
The bone marrow aspirate was obtained from the 
iliac crest via percutaneous puncture using the standard 
technique (Figure 2). Six punctures were made to obtain 
about 12 ml of bone marrow, not to exceed a volume of 
2 ml per puncture. After each puncture, the needle was 
repositioned(21). This material was anticoagulated with 
sodium citrate in the ratio of 1:5 citrate:bone marrow.
The biological bone graft was formed by adding the 
bone marrow aspirate to the platelet concentrate. Once 
the gel was formed, the surgeon placed the material in 
the surgical site (Figure 3).
For the evaluation of bleeding as a result of surgery, 
the RBC indices of hemoglobin (Hb) and hematocrit 
(Ht) were obtained(7). These indices were obtained on 
the day of surgery and 24 hours postoperatively. In this 
manner, the variation of these indices before and after 
surgery was obtained. The groups were compared with 
respect to these variables (change in hemoglobin and 
hematocrit) by Student’s t-test.
Pain assessment was performed using the visual ana-
log scale for pain(22,23), performed 24 hours after surgery. 
The groups were compared with respect to this variable 
by Student’s t-test.
Figure 2 – Obtaining the bone marrow aspirate.
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RESULTS
There were no differences between the iliac and 
PRP groups in relation to the variation of levels of 
hemoglobin and hematocrit pre- and postoperatively 
(Tables 3 and 4).
Pain assessment performed using the visual analog 
scale for pain (VAS) was not different between groups 
(Table 5).
Figure 3 – Placing the biological graft at the osteotomy site.
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Table 3 – Changes in hemoglobin (Hb) levels.
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Tabela 4 – Changes in hematocrit (Ht) levels.
Iliac 
(n = 14)
PRP
(n = 11)
Total
Difference in Ht Mean 6.4 5.3 5.9
pre- and 
postoperatively
SD 2.3 3.1 2.7
p = 0.323 Median 5.9 5.7 5.7
Minimum 2.3 0.3 0.3
Maximum 10.8 9.2 10.8
P value regarding the Student’s t-test.
Table 5 – Visual analog scale for pain(22).
Iliac 
(n = 14)
PRP
(n = 11)
Total
Pain scale Mean 5.1 4.4 4.8
p = 0.538 SD 2.9 2.7 2.8
Median 6.0 3.0 5.0
Minimum 1.0 1.0 1.0
Maximum 9.0 9.0 9.0
P value regarding the Student’s t-test.
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Iliac
(n = 14)
PRP
(n = 11)
Total
Difference in 
Hb
Mean 2.3 2.2 2.3
pre- and 
postoperatively
SD 1.0 0.7 0.9
p = 0.820 Median 2.4 2.1 2.2
Minimum -0.3 0.9 -0.3
Maximum 3.7 3.2 3.7
P value regarding the Student’s t-test.
Platelet-rich plasma (PRP) has important 
osteoinductive properties, as has been demonstrated 
by several experimental studies(11,28-31). PRP has 
wide clinical application in the field of oral and 
maxillofacial surgery and is used as an osteopromotive 
agent in various situations(31-33). Its clinical use in 
orthopedics has been increasing, despite the absence 
of randomized prospective studies to assess the results 
of its application(30,34-36).
In a study that aims to evaluate the effectiveness 
of PRP alone or in combination with other materials, 
it is important to remember that different methods 
are used to obtain PRP(1,5,30), and the ability to obtain 
high concentrations of platelets is variable among the 
available methods. Most systems used in clinical practice 
are based on centrifugation; the centrifuges used for this 
purpose have been developed for diagnosis and not to 
obtain PRP, which is often generated with less than ideal 
platelets level. The method of obtaining PRP used in our 
study(37) is able to offer a platelet concentration above 
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The need for an autologous graft in TOAMW is 
considered a disadvantage by many surgeons, because of 
the morbidity associated with obtaining the autologous 
graft(38,39). Pain is a frequent complaint in patients who 
undergo obtainment of autologous grafting. In our study 
there was no difference in pain between the groups after 
24 hours (p = 0.538).
PRP was used in TKA(6,7), reducing bleeding and the 
occurrence of arthrofibrosis. In our model of the clinical 
application, the proximal tibial osteotomy by addition 
of a medial wedge, there was no difference in bleeding 
between the groups with the use of PRP associated with 
bone marrow aspirate (p = 0.820 and p = 0.323).
CONCLUSION
The use of PRP associated with bone marrow in 
TOAMW showed no advantages over the use of autologous 
iliac bone graft with regard to pain and bleeding.
DISCUSSION
The valgus osteotomy of the tibia using the technique 
of adding a medial wedge is a common procedure in the 
treatment of several orthopedic pathologies, and today 
it has been thoroughly standardized(18,24-27).
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